Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on April 21, 2020, reporting events occurring on April 15 and April 17, 2020. The Company is currently in the process of winding down its operations. Note: The request metadata references "Vivani Medical, Inc.," but the filing text explicitly identifies the registrant as Second Sight Medical Products, Inc.
Key Financial Metrics and Liquidity
The filing does not provide comprehensive revenue, profit, or cash flow statements. However, it discloses specific liquidity and liability events:
- Unpaid Rent: The Company received a notice of default for failure to pay base rent and operating expenses totaling $115,697 for its principal facility in Sylmar, California.
- Severance Liability: The Company owes approximately $489,000 in unpaid severance payments to its former Chief Operating Officer, Patrick Ryan.
- Executive Compensation: The Board approved compensation of $400 per hour for Matthew Pfeffer, serving as Acting Chief Executive Officer since March 30, 2020.
Material Changes and Operational Events
- Workforce Reduction: On April 17, 2020, the Company executed a second round of layoffs, terminating 15 employees, including the Chief Operating Officer, as part of its wind-down strategy.
- Leadership Change: Matthew Pfeffer, a board member and chair of the audit committee, was appointed Acting Chief Executive Officer effective March 30, 2020.
- Lease Default: The Company is in default on its primary lease agreement, facing potential eviction and litigation if a resolution is not reached with the lessor.
Guidance, Risks, and Contingencies
Nasdaq Listing Compliance
On April 15, 2020, Nasdaq notified the Company of non-compliance with Listing Rule 5605 regarding independent director and audit committee requirements, triggered by the appointment of an insider as Acting CEO. The Company has been granted a cure period until the earlier of its next annual shareholders' meeting or March 27, 2021 (or September 23, 2020, if the meeting occurs before that date). Failure to comply may result in delisting.
Legal and Operational Risks
The Company faces significant risks related to its wind-down operations, including:
- Potential litigation and substantial legal expenses arising from the lease default.
- Delisting from Nasdaq, which could restrict trading to over-the-counter markets and reduce analyst coverage.
- Adverse effects on the ability to fund the business plan if delisting occurs.
Investor Verification Checklist
- Verify the current status of the lease negotiations and whether the $115,697 rent default has been resolved.
- Confirm the Company's plan to regain Nasdaq compliance regarding independent director requirements before the cure period expires.
- Monitor the Company's cash position to ensure it can meet the $489,000 severance obligation and other wind-down costs.
- Review the timeline for the next annual shareholders' meeting to determine the exact deadline for Nasdaq compliance.